J Clin Oncol: ROCK2 inhibitor berudil can effectively treat refractory chronic graft-versus-host disease

The rho-related coiled-coil protein kinase 2 (ROCK2) signaling pathway regulates the Th17/regulatory T cell balance and controls the fibrotic pathway.

A Phase IIa, open-label dose exploratory study " ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease " published in the " Journal of Clinical Oncology " recently , aimed at clarifying Beludi The dose and effect of ER for cGVHD patients who have previously received first-line third-line therapy (LOT).

A total of 54 cGVHD patients were recruited, and the median time from diagnosis of cGVHD to enrollment was 20 months.

Remission rate of different groups

With a median follow-up of 29 months, the ORR (95% CI) of berudil at doses of 200 mg·1/day, 200 mg·2/day, and 400 mg·1/day were 65% (38%- 86%), 69% (41%-89%) and 62% (38%-82%) .

Duration of remission of berudil treatment

The remission rate is clinically significant, with a median duration of remission of 35 weeks, and is associated with improved quality of life and reduced corticosteroid (CS) consumption.

The failure-free survival rates at 6 months and 12 months were 76% (62%-85%) and 47% (33%-60%), respectively.

Remission rate of different organs

Beludil is well tolerated and the incidence of cytopenias is low.

In short, berudil treatment can enable patients to obtain high ORR and overall survival rate, and at the same time can improve the quality of life of patients, reduce CS dose and limit toxicity .

Original source:

Madan Jagasia, et al.